Literature DB >> 17587566

PRMT2, a member of the protein arginine methyltransferase family, is a coactivator of the androgen receptor.

Rene Meyer1, Siegmund S Wolf, Maik Obendorf.   

Abstract

The basal transcriptional activity of nuclear receptors (NRs) is regulated by interactions with additional comodulator proteins (coactivator/corepressor). Here, we describe a new androgen receptor (AR)-associated coactivator, PRMT2, which belongs to the arginine methyltransferase protein family. To search for AR-interacting proteins a fragment of the AR was used in a library screen exploiting the yeast two-hybrid technique and identifying the C-terminal region of PRMT2. We demonstrated that PRMT2 acts as a strong coactivator of the AR, had modest or none influence on transcriptional activation mediated by other NRs. Interestingly, PRMT2 interaction with the estrogen receptor (ER) was strongly dependent on the cellular background, thus, suggesting the involvement of additional, differentially expressed coregulators. We also demonstrated synergistic interaction of PRMT2 with other known nuclear receptor coactivators, such as GRIP1/TIF-2. Potentiation of AR-mediated transactivation by PRMT2 alone and in synergism with GRIP1 was prevented by a competitive inhibitor of methyltransferase activity. The PRMT2 expression profile overlaps with the distribution of AR, with strongest PRMT2 abundance in androgen target tissues. Immunofluorescence experiments showed that the intracellular localization of PRMT2 depends on the presence of the cognate receptor ligand. Under androgen-free conditions, both AR and PRMT2 are confined to the cytoplasm, whereas in the presence of androgens both proteins colocalize and translocate into the nucleus. Treatment with the AR antagonist hydroxyflutamide results in nuclear translocation of the AR, but not the coactivator PRMT2. Thus, it appears that the ligand-dependent AR conformation is essential for the recruitment and nuclear translocation of PMRT2 which acts as AR-coactivator, presumably by arginine methylation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17587566     DOI: 10.1016/j.jsbmb.2007.05.006

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  31 in total

Review 1.  Histone arginine methylation.

Authors:  Alessandra Di Lorenzo; Mark T Bedford
Journal:  FEBS Lett       Date:  2010-11-11       Impact factor: 4.124

Review 2.  Small Molecule Inhibitors of Protein Arginine Methyltransferases.

Authors:  Hao Hu; Kun Qian; Meng-Chiao Ho; Y George Zheng
Journal:  Expert Opin Investig Drugs       Date:  2016-02-16       Impact factor: 6.206

3.  p150/glued modifies nuclear estrogen receptor function.

Authors:  Soo Jung Lee; Christina Chae; Michael M Wang
Journal:  Mol Endocrinol       Date:  2009-02-19

Review 4.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 5.  The role of histone demethylases in cancer therapy.

Authors:  Inga Hoffmann; Martin Roatsch; Martin L Schmitt; Luca Carlino; Martin Pippel; Wolfgang Sippl; Manfred Jung
Journal:  Mol Oncol       Date:  2012-08-07       Impact factor: 6.603

6.  Protein-arginine methyltransferase 1 suppresses megakaryocytic differentiation via modulation of the p38 MAPK pathway in K562 cells.

Authors:  Yuan-I Chang; Wei-Kai Hua; Chao-Ling Yao; Shiaw-Min Hwang; Yi-Chi Hung; Chih-Jen Kuan; Jiun-Shyang Leou; Wey-Jinq Lin
Journal:  J Biol Chem       Date:  2010-05-04       Impact factor: 5.157

7.  PRMT2 and RORγ expression are associated with breast cancer survival outcomes.

Authors:  Tae Gyu Oh; Peter Bailey; Eloise Dray; Aaron G Smith; Joel Goode; Natalie Eriksson; John W Funder; Peter J Fuller; Evan R Simpson; Wayne D Tilley; Peter J Leedman; Christine L Clarke; Sean Grimmond; Dennis H Dowhan; George E O Muscat
Journal:  Mol Endocrinol       Date:  2014-06-09

Review 8.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 9.  Protein arginine methyltransferases and cancer.

Authors:  Yanzhong Yang; Mark T Bedford
Journal:  Nat Rev Cancer       Date:  2012-12-13       Impact factor: 60.716

Review 10.  Mouse models of Down syndrome: gene content and consequences.

Authors:  Meenal Gupta; A Ranjitha Dhanasekaran; Katheleen J Gardiner
Journal:  Mamm Genome       Date:  2016-08-18       Impact factor: 2.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.